Loading
NASDAQHealthcareBiotechnology
Latest quote
$4.11
+$0.04 · +0.98%
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
Previous close
$4.11
+$0.04 · +0.98%
After-hours
$4.1323
+$0.0223 · +0.54%
Oct 9, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
Day range
Current $4.11
52-week range
Current $4.11
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
31
Expensive
Sentiment
54
Mixed
Risk
71
High Risk
Momentum
27
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
Day range
Current $4.11
52-week range
Current $4.11
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | 675K USD | 951K USD | — |
| Cost of goods sold | 572K USD | — | — | — | — |
| Gross profit | −572K USD | — | 675K USD | 951K USD | — |
| Research and development | 9.12M USD | 20.01M USD | 12.9M USD | 12.44M USD | 6.08M USD |
| Selling, general, and administrative | 20.4M USD | 12.1M USD | 8.55M USD | 6.57M USD | 2.9M USD |
| Operating expenses | 28.95M USD | 32.12M USD | 21.45M USD | 19M USD | 8.98M USD |
| Interest income | 1.01M USD | 1.26M USD | 615K USD | — | — |
| Interest expense | 71K USD | 71K USD | 82K USD | 6K USD | 628K USD |
| Depreciation and amortization | 572K USD | 428K USD | 284K USD | 161K USD | 13K USD |
| Operating income | −29.52M USD | −32.12M USD | −20.77M USD | −18.05M USD | −8.98M USD |
| Net income | −26.56M USD | −36.73M USD | −30.54M USD | −18.06M USD | −10.02M USD |
Company facts updated Oct 10, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI4.19M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM2.56M0.00%78.27B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF1.25M0.00%95.4B USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO817.95K0.01%13.97B USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO730.69K0.00%18B USD0.06%$112.66+0.50%
Dimensional - US Small Cap ETFDFAS320.04K0.00%33.87B USD0.31%$78.35+0.32%
iShares Micro-Cap ETFIWC316.09K0.02%1.32B USD0.60%$183+0.11%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC174.11K0.02%1.04B USD0.20%$86.29+0.43%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASiShares Micro-Cap ETFIWCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
